What is the proper technique for intramuscular injection in the gluteal region and how should Nicolau syndrome be managed if it occurs?

Proper Intramuscular Injection Technique in the Gluteal Region

For intramuscular injections in the gluteal region, target the posterior lateral aspect of the upper buttocks and flanks, use a 4-mm needle at 90 degrees for subcutaneous injections (or appropriate length needle with skin lift for true IM injections), and systematically rotate sites at least 1 cm apart to prevent lipodystrophy. 1, 2

Critical Distinction: Subcutaneous vs. Intramuscular

The most recent guidelines (2025,2016) from Mayo Clinic Proceedings focus primarily on subcutaneous insulin and GLP-1 receptor agonist injections, not traditional intramuscular injections 1, 2. However, the anatomical principles apply to both:

For Subcutaneous Injections (Insulin, GLP-1 agonists):

• Site: Posterior lateral aspect of both upper buttocks and flanks 2
• Needle: 4-mm pen needles at 90° for all adults regardless of BMI 2
• Technique: No skin lift needed with 4-mm needles; use lifted skinfold if needle >4 mm 2

For True Intramuscular Injections:

The evidence reveals a critical safety concern: the dorsogluteal region poses significant risk of neurovascular injury and is prone to complications, particularly in obese patients 3, 4, 5.

Optimal Injection Site Selection

The ventrogluteal site is safer than the dorsogluteal site for true IM injections, with greater distance from neurovascular structures (13.87 mm vs. 6.83 mm from superior gluteal artery) 4. However, recent cadaver studies show the dorsogluteal region may have higher success rates in obese patients due to greater muscle thickness 5.

Key Anatomical Considerations:

• Ventrogluteal: 22.22 mm muscle thickness, 13.87 mm from superior gluteal artery 4
• Dorsogluteal: 28.35 mm muscle thickness, but only 6.83 mm from superior gluteal artery 4
• Obesity factor: Mean gluteal fat thickness can reach 54 mm in obese patients (BMI >40) 3

Systematic Rotation Protocol

Divide injection zones into quadrants or halves, using one zone per week 1:

• Inject at least 1 cm apart (approximately one adult finger width) 1
• Rotate in a consistent direction within each zone 1
• Avoid areas with lipodystrophy, scars, or previous complications 2
• Never inject through clothing 1

Critical Pitfall: Nicolau Syndrome

Nicolau syndrome is a rare but devastating complication causing local ischemic necrosis following IM injection, most commonly with NSAIDs (especially diclofenac) and penicillin 3, 6, 7, 8, 9, 10.

Risk Factors:

• Obesity (BMI >40) with thick subcutaneous fat layer 3
• Standard needle length (3.8 cm) inadequate for obese patients 3
• Injection into adipose tissue instead of muscle 3
• NSAIDs, particularly diclofenac sodium 3, 7, 9, 10

Clinical Presentation:

• Severe pain during or immediately after injection 9, 10
• Rapid progression to skin discoloration (violaceous/dark patches) 9, 11
• Ischemia followed by tissue necrosis and ulceration 6, 8, 9
• Can occur within hours to days post-injection 6

Management of Nicolau Syndrome

If Nicolau syndrome develops, initiate immediate wound care with surgical debridement of necrotic tissue, combined with hyperbaric oxygen therapy (HBOT) when available 6, 7, 8:

Treatment Algorithm:

1. Immediate recognition: Severe injection pain + rapid skin discoloration = NS until proven otherwise 9, 10
2. Early intervention (within 5-33 days optimal for HBOT) 6:
   • Local wound care with topical antibiotics 7, 11
   • Intravenous antibiotics if infection present 7, 10
   • Analgesics for pain control 10
3. Surgical debridement of necrotic tissue 7, 10
4. HBOT: 30 sessions can achieve complete healing 8
   • Enhances tissue oxygenation 8
   • Promotes wound healing 6, 8
   • Effective even when started days after onset 6
5. Wound closure:
   • Primary closure for smaller defects 3, 7
   • Fasciocutaneous flap for larger defects (5 of 9 patients in one series) 7

Expected Outcomes:

• Complete healing possible with residual hypopigmented scarring 8, 11
• Follow-up 2-30 months shows satisfactory aesthetic and functional results 7
• No wound complications (infection, dehiscence, seroma) when properly managed 7

Prevention Strategies

Avoid IM injections in obese patients whenever possible; if necessary, use needles of appropriate length to reach muscle tissue 3:

• Standard 3.8 cm needles inadequate when gluteal fat >54 mm 3
• Consider alternative routes (oral, IV) for NSAIDs in high-risk patients 3
• Proper injection technique with individual clinical assessment 4
• Awareness that NS can develop despite following all guidelines 6